Medtronic (MDT) announced the start of the Embrace Gynecology investigational device exemption U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery system in robotic-assisted gynecological procedures. The first procedures, total hysterectomies, were successfully completed at AHN West Penn Hospital in Pittsburgh, PA, by Dr. Sarah Crafton and Dr. Eirwen Miller, Embrace Gynecology study surgeons at Allegheny Health Network. Embrace Gynecology is a prospective multicenter study to evaluate the safety and effectiveness of the Hugo RAS system when used during hysterectomy procedures, inclusive of those being treated for malignancies. The study will enroll up to 70 patients across up to 5 U.S. hospitals.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $112 from $101 at Citi
- Medtronic’s Strategic Growth Potential with Spyral RDN Technology Justifies Buy Rating
- Medtronic call volume above normal and directionally bullish
- Medtronic Issues €1.5 Billion in Senior Notes
- Medtronic’s NIM Vital™ System Study Completion: A Boost for Investor Confidence